Lupin Limited has revised the timeline for its subsidiary Nanomi B.V. to acquire a minority stake in Multicare Pharmaceuticals Philippines, Inc. The transaction, initially expected to close by the end of May 2026, is now scheduled for completion in July 2026, subject to the satisfaction of specific closing conditions.

Nanomi B.V., a wholly owned subsidiary of Lupin Limited, had entered into definitive agreements on April 01, 2026, to purchase the shares from existing shareholders of Multicare Pharmaceuticals Philippines, Inc. The target company is already a subsidiary of Nanomi. The disclosure confirms that the transaction remains in progress but has not yet reached the closing stage.

The update was submitted to the National Stock Exchange of India Limited and BSE Limited in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Amit Kumar Gupta, Company Secretary & Compliance Officer of Lupin Limited.

Transaction Details

Lupin Limited announced that results from its Phase 1a trial evaluating LNP8701 have been accepted for publication at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, held from May 29-June 2, 2026, in Chicago, IL. The abstract reports findings from an ongoing first-in-human study of LNP8701, an orally administered SOS1 inhibitor designed to block SOS1-mediated RAS activation. Results indicate that LNP8701 was well tolerated with a desirable safety profile and favorable anti-tumor activity.

The preliminary efficacy findings demonstrate that two patients completed LNP8701 monotherapy for 12 cycles and one patient completed 14 cycles with stable disease. Vinita Gupta, CEO, Lupin, said the findings highlight the emerging potential of LNP8701 and signal progress in the pursuit of novel therapies for difficult-to-treat cancers.

Current data suggest that LNP8701 is safe and well-tolerated across all tested dosing levels. Lupin will continue to study the efficacy of LNP8701 in its phase 1b trial in India and explore its potential to treat solid tumors both as a monotherapy and as part of a combination.

Abstract Details